Telehealth Marketing
Telehealth ads live under more rules than most: platform health policies, FDA and FTC claims, state licensure. We’ve run creative for weight-loss and mental health telehealth brands, and we build every ad with those lines in mind from the first draft.
Sound Familiar?
Health claims and personal-attribute rules trip up copy that looked fine in the brief.
The same three concepts have run for months, and results are sliding.
Every new ad waits in a review queue, so testing stalls.
Growth wants ten new ideas a week. The design team can make three.
What We Do for You
Creative that converts, built on claims you can stand behind.
02
A claims library and banned phrase list every designer works from.
03
Educational content that builds trust before patients sign up.
05
Condition pages and pre-qualification flows that cut wasted spend.
06
Approval rate, creative fatigue and cost per qualified signup.
Results
Since 2023 we’ve made GLP-1 explainer videos, myth vs fact posts and product content for telehealth brands, each one built on approved claims. For one GLP-1 brand, that work has added up to:
Free Creative Audit
We review your current ads and social against platform rules and this year’s enforcement, then send three sample designs made in your branding.
Sample layouts. Yours are made with your logo, colors and approved claims.
The Guide
If you market a telehealth brand, we’d recommend writing compliance into the creative brief from day one. Rejected ads, paused accounts and warning letters all cost more than getting the claim right the first time, and 2026 gave telehealth marketers plenty of all three.
Telehealth is one of the hardest categories to market well. You’re selling a medical service, often tied to a prescription, to people who are scrolling past everything else in their feed. The FDA, the DEA, Meta and Google each have their own rules, and those rules changed several times this year.
We work with telehealth brands on social, paid creative and content, including weight-loss and GLP-1 programs. This guide covers what makes the category different, what regulators and platforms flagged this year, the ad rules in plain words, the content that works, how to make more creative without more risk, what changes in 2027 and when to bring in a creative partner.
This guide is general information, not legal or regulatory advice. Have your compliance lead or counsel review anything that makes a medical or drug claim.
In This Guide
Most consumer brands can test a bold claim and see what happens. Telehealth brands can’t. Three things set the category apart.
The product is a medical decision. A patient isn’t buying a sweater. They’re deciding whether to trust you with their health, and often with a prescription. That raises the bar for trust before anyone clicks “Get started.”
More than one regulator is watching. The FDA looks at drug claims. The FTC looks at advertising and endorsements. The DEA controls how controlled substances can be prescribed through telemedicine. State medical boards and licensure rules decide where your clinicians can treat. Your ad has to work for all of them at once.
The platforms have their own rules on top. Meta and Google both require certification before you can advertise prescription drugs or online pharmacy services, and both restrict how you talk about health conditions. An ad can be legal and still get rejected.
The good news is that the brands that get this right build a real advantage. Competitors who cut corners get paused, warned or banned, and the compliant brands keep running.
2026 was a busy year for telehealth enforcement, especially around compounded GLP-1 weight-loss drugs.
On March 3, 2026, the FDA announced it had sent warning letters to 30 telehealth companies over how they marketed compounded GLP-1s. The FDA called it the second group of letters in a crackdown on misleading direct-to-consumer drug ads that began in September 2025. According to Sheppard Mullin, the FDA sent another 25 letters to telehealth companies during the week of June 15, 2026.
Two problems came up again and again in the FDA’s announcement:
If you run a GLP-1 program, look at your ads, landing pages and social captions with those two problems in mind. Then look at anything an affiliate or creator says on your behalf, because the same rules apply to them.
Coming soon: What the FDA’s GLP-1 Warning Letters Teach Telehealth Marketers
Here’s how we’d sum up the two biggest ad platforms for telehealth brands. Policies change often, so check the current version before you launch a campaign.
That last rule causes more rejections than anything else we see. “Struggling with your weight?” points at the viewer. “Weight care from licensed clinicians, from home” describes the service. The second version usually gets approved, and it often performs just as well.
Coming soon: Advertising Telehealth on Meta and Google: Certification, Targeting and Claims
The telehealth brands that grow steadily are usually the ones that teach. Educational content does three jobs at once. It builds trust, it gets approved more often, and it gives patients a reason to come back before they’re ready to sign up.
Here’s the content mix we’d recommend:
We’d keep testimonials and before-and-after content to a minimum, and only with written consent and a compliance review. Results claims are where telehealth brands get into trouble, with regulators and with the platforms.
Coming soon: Myth vs Fact: An Educational Content System for Telehealth Brands
Free Audit
We’ll review your ads against platform rules and send three sample designs in your branding.
Paid social runs on fresh creative. Ads wear out, and the brands that win usually test more concepts than their competitors. The problem in telehealth is that every new ad is another chance to make a claim you can’t support.
What’s worked for us is building the compliance rules into the system, so volume and safety stop pulling against each other.
Start with an approved claims library. Before anyone designs an ad, write down the claims you’re allowed to make, the exact wording and the source for each one. Have your compliance lead approve the list once. Then every designer and copywriter works from it.
Write a banned phrases list too. “Same as,” “equivalent to,” “FDA-approved” (for compounded products), and any line that tells the viewer what condition they have. Put it at the top of the brief.
Separate the concept from the claim. Most ad testing is about the hook, the format and the visual, not the medical claim. Test ten hooks with the same approved claim underneath.
Batch your reviews. Instead of sending ads to compliance one at a time, review them in weekly batches. That keeps volume up without turning your compliance lead into a bottleneck.
Keep a record. Log what was approved, when and by whom. If a platform or regulator asks, you’ll have the answer.
When we worked with a GLP-1 telehealth brand, this system is what let us keep new creative going out every week without slowing down for approvals. That work has run since 2023 and covers explainer videos, myth vs fact posts and product content.
The biggest date on the calendar is December 31, 2026.
The DEA’s current telemedicine flexibilities let clinicians prescribe controlled substances through telemedicine without an in-person visit first. That fourth extension runs through December 31, 2026.
As of early November, the DEA’s permanent “special registration” rule wasn’t final. The Alliance for Connected Care reports the final rule went to White House review on August 25, 2026, with publication forecast for November. On November 2, a group of patient and provider organizations asked the DEA for another extension through at least December 31, 2027.
If your brand prescribes controlled substances, including some mental health and ADHD treatments, we’d recommend two things now:
Brands that don’t prescribe controlled substances should still pay attention. Patients don’t always know the difference, and some will assume all telehealth is changing. A short, calm post explaining what does and doesn’t affect your patients can prevent cancellations.
We also expect the FDA to keep sending warning letters on drug advertising in 2027. Nothing we’ve seen suggests this enforcement is slowing down.
Coming soon: DEA’s Dec 31 Telemedicine Deadline: What to Tell Patients Now
Coming soon: Telehealth Marketing in 2027: What Changes Jan 1
Telehealth marketing reports often stop at cost per click and cost per lead. Those matter, but they leave out the numbers that show whether your creative is healthy. Each month, we’d track:
Plenty of telehealth brands run creative in-house, and some do it very well. We’d recommend bringing in outside help when:
Look for a partner who has worked inside healthcare ad rules before, who will work from your approved claims, and who builds review into their process rather than leaving it to you.
If you’re not sure where your creative stands, we offer a free creative audit for telehealth brands. We review your current ads and social against platform rules and recent enforcement, then send three sample designs made in your branding so you can see the difference for yourself.
Do we need LegitScript certification to run telehealth ads?
If your ads promote prescription drugs or online pharmacy services, Meta and Google both require LegitScript certification, plus their own authorization. Meta says ads that promote telehealth services in general, without prescription drug claims, don’t need that authorization. Check each platform’s current policy before you launch.
Can we say our compounded GLP-1 is the same as a brand-name drug?
We’d recommend against it. In its March 2026 warning letters, the FDA flagged claims implying that compounded drugs are the same as FDA-approved products. Describe your program, your clinicians and your process instead.
Why do our health ads keep getting rejected on Meta?
The most common reason we see is copy that implies the viewer has a health condition, such as “Struggling with anxiety?” Meta’s personal attributes policy bans that. Rewrite the ad to describe the service and its benefits.
Resources
Free tools and practical guides for creative that converts and clears review.
Free Audit
We review your current ads and social creative and send a short written report on what to fix first.
Articles
Guides on ad policies, claims, landing pages and patient retention.
We’ll review your current creative and send a short written report.
